The National Institutes of Health's alcohol chief told an industry official in an email he would stop research about marketing to teens; California sues Sutter Heath, alleging antitrust violations; whether the Department of Veterans Affairs chief resigned or not could have broader implications for the agency.
The director of the National Institutes of Health’s Institute on Alcohol Abuse and Alcoholism (NIAAA), George Koob, told the alcohol beverage industry he would stop certain research to which the industry objected and subjected 2 academic researchers to a profanity-laced tirade, according to STAT. The reasearchers, from Boston University and Johns Hopkins University, had published respected papers about alcohol marketing and teenagers, angering the industry. The industry official Koob had emailed previously worked at NIAAA. Other publications have previously reported that Koob was trying to get industry funding for studies to see whether “moderate” drinking was good for the heart.
California’s attorney general filed an antitrust lawsuit against Sutter Health, the dominant healthcare system in the northern part of the state, and accused it of overcharging consumers and employers, CaliforniaHealthline reported. The lawsuit comes as concerns grow about national consolidation among hospitals, insurers, and other industry middlemen. The lawsuit alleged Sutter uses a variety of improper tactics, such as gag clauses on prices, “punitively high” out-of-network charges, and “all-or-nothing” contract terms that require all of its facilities to be included in insurance networks.
Any formal reform actions Robert Wilkie takes as acting secretary of the Department of Veterans Affairs could face a legal challenge, Politico reported, as a debate played out over the weekend as to whether David Shulkin, MD, resigned or was fired by President Donald Trump. By naming Wilkie, a Defense Department official, Trump bypassed Shulkin’s deputy, who was next in line to succeed him. That decision has reignited a debate among legal experts about the president’s ability to select replacements for ousted Cabinet secretaries. The debate centers on vague language in a 1998 law which gives the president broad authority to temporarily fill a vacancy at a federal agency with an acting official if the current office holder “dies, resigns, or is otherwise unable to perform the functions and duties of the office.” Shulkin is denying that he resigned. Some legal experts note that the law does not explicitly grant that authority to the president in the case of firings. That could make Trump’s decision to appoint Wilkie a potential test of presidential authorities.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More